MedTrace Logo

Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions

NCT04232592 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-01-18

No results posted yet for this study

Summary

To observe the clinical safety of intrauterine injection of human embryonic stem cell derived mesenchymal cells in the treatment of moderate and severe intrauterine adhesion, and to preliminarily explore its clinical effectiveness in promoting endometrial regeneration and repair.

Conditions

  • Intrauterine Adhesion

Interventions

BIOLOGICAL

Inject a solution of stem cell preparation

The control group was injected with a solution of stem cell preparation

BIOLOGICAL

Inject stem cells

Three dose groups were designed: low dose group, medium dose group and high dose group.

Sponsors & Collaborators

  • Tongji Hospital

    collaborator OTHER

  • Qi Zhou

    lead OTHER_GOV

Principal Investigators

  • Qi Zhou, Doctor · Institute of Zoology, Chinese Academy of Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2022-01-31
Completion
2022-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232592 on ClinicalTrials.gov